ASCO 2021 | Beyond anti-PD-1 and anti-CTLA-4 in melanoma

The introduction of immunotherapy transformed the melanoma treatment landscape. The approval of immune checkpoint inhibitors, such as ipilimumab, was a milestone both in the treatment of melanoma and the wider development of immune-targeting agents in oncology. Pauline Funchain, MD, Cleveland Clinic, Cleveland, OH, discusses the latest in immunotherapy research and beyond in melanoma. Once major area of investigation is looking at effective options for patients with primary and acquired resistance to checkpoint blockade. Dr Funchain highlights combination approaches and tumor infiltrating lymphocytes as areas of promise. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.